

Status: Path 1 of [Dialog Information Services via Mode

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

***** HHHHHHHH SSSSSSS? *****

Welcome to DIALOG

Status: Connected

Dialog level 01.10.01D

Last logoff: 25oct01 12:53:29

Logon file405 26oct01 12:18:56

*** ANNOUNCEMENT ***

--Important Notice to Freelance Authors--

See HELP FREELANCE for more information

NEW FILES RELEASED

***Disclosure Database (File 101)

***Harris Business Profiler (File 537)

***Mergent Company Profiles (File 555)

***Mergent Company Snapshots (File 556)

***Mergent Company News Reports (File 557)

***Financial Times Fulltext (File 476)

***TRADEMARKSCAN-Japan (File 669)

UPDATING RESUMED

***Delphes European Business (File 481)

***Books In Print (File 470)

RELOADED

***CLAIMS/US PATENTS (Files 340, 341, 942)

***Kompass Middle East/Africa/Mediterranean (File 585)

***Kompass Asia/Pacific (File 592)

***Kompass Central/Eastern Europe (File 593)

***Kompass Canada (File 594)

***CANCERLIT (File 159)

***Information Science Abstracts (File 202)

New document supplier

IMED has been changed to INFOTRIE (see HELP OINFOTRI)

>>>Get immediate news with Dialog's First Release
news service. First Release updates major newswire
databases within 15 minutes of transmission over the
wire. First Release provides full Dialog searchability
and full-text features. To search First Release files in
OneSearch simply BEGIN FIRST for coverage from Dialog's
broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HIGHLIGHT set on as ''

PICKS is set ON as an alias for 5,55,159,143,358,340,344,348,351,352,447,72,73,154,1

55,349.

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.7.8 term=ASCII

*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2000 The Dialog Corporation plc All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

?b picks

```
>>>      351 is unauthorized
>>>      352 is unauthorized
>>>2 of the specified files are not available
      26oct01 12:19:18 User243038 Session D84.1
      $0.00      0.207 DialUnits FileHomeBase
$0.00 Estimated cost FileHomeBase
$0.02 TYMNET
$0.02 Estimated cost this search
$0.02 Estimated total session cost      0.207 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2001/Oct W3
(c) 2001 BIOSIS

File 55:Biosis Previews(R) 1993-2001/Oct W3
(c) 2001 BIOSIS

File 159:Cancerlit 1975-2001/Sep
(c) format only 2001 Dialog Corporation

File 143:Biol. & Agric. Index 1983-2001/Sep
(c) 2001 The HW Wilson Co

File 358:Current BioTech Abs 1983-2001/Sep
(c) 2001 DECHEMA

***File 358: Updates delayed. Please see HELP NEWS 358 for details.**

File 340:CLAIMS(R)/US PATENT 1950-01/Oct 16
(c) 2001 IFI/CLAIMS(R)

***File 340: has been reloaded. Published applications are available.**
See HELP NEWS 340 for details.

File 344:CHINESE PATENTS ABS APR 1985-2001/Sep
(c) 2001 EUROPEAN PATENT OFFICE

File 348:EUROPEAN PATENTS 1978-2001/Oct W02
(c) 2001 European Patent Office

File 447:IMSWorld Patents International 2001/Sep
(c) 2001 IMSWorld Publ. Ltd.

File 72:EMBASE 1993-2001/Oct W3
(c) 2001 Elsevier Science B.V.

***File 72: For information about Explode feature please**
see Help News72.

File 73:EMBASE 1974-2001/Oct W3
(c) 2001 Elsevier Science B.V.

***File 73: For information about Explode feature please**
see Help News73.

File 154:Medline(R) 1990-2001/Nov W3

File 155:MEDLINE(R) 1966-2001/Nov W3

File 349:PCT Fulltext 1983-2001/UB=20011018,UT=20011011

(c) 2001 WIPO/Univentio

***File 349: Additional fulltext records and images will be added**
shortly. Additional coverage added. See HELP NEWS 349.

Set	Items	Description

?s e-cadherin		
S1	3306	E-CADHERIN
?s s1 and endothelin B receptor		
	3306	S1
	4105	ENDOTHELIN B RECEPTOR
S2	0	S1 AND ENDOTHELIN B RECEPTOR
?s catenin?		
S3	16499	CATENIN?
?s s3 and s1		
	16499	S3
	3306	S1
S4	1160	S3 AND S1
?s endothelin B receptor		
S5	4105	ENDOTHELIN B RECEPTOR
?s s5 and s4		
	4105	S5
	1160	S4
S6	0	S5 AND S4
?ds		

Set	Items	Description
S1	3306	E-CADHERIN
S2	0	S1 AND ENDOTHELIN B RECEPTOR
S3	16499	CATENIN?
S4	1160	S3 AND S1
S5	4105	ENDOTHELIN B RECEPTOR
S6	0	S5 AND S4
?s s1 and cancer?		
	3306	S1
	2982891	CANCER?
S7	1040	S1 AND CANCER?
?s s7 and s5		
	1040	S7
	4105	S5
S8	0	S7 AND S5
?s s7 and endothelium antagonist?		
	1040	S7
	0	ENDOTHELIAL ANTAGONIST?
S9	0	S7 AND ENDOTHELIAL ANTAGONIST?
?ds		

Set	Items	Description
S1	3306	E-CADHERIN
S2	0	S1 AND ENDOTHELIN B RECEPTOR
S3	16499	CATENIN?
S4	1160	S3 AND S1
S5	4105	ENDOTHELIN B RECEPTOR
S6	0	S5 AND S4
S7	1040	S1 AND CANCER?
S8	0	S7 AND S5
S9	0	S7 AND ENDOTHELIAL ANTAGONIST?
?s sy and treat?		
Processing		
Processed	10 of 14 files	...
Completed processing	all files	
10272	SY	

8141373 TREAT?
 S10 3690 SY AND TREAT?
 ?s s7 and treat?
 1040 S7
 8141373 TREAT?
 S11 132 S7 AND TREAT?
 ?ds

Set	Items	Description
S1	3306	E-CADHERIN
S2	0	S1 AND ENDOTHELIN B RECEPTOR
S3	16499	CATENIN?
S4	1160	S3 AND S1
S5	4105	ENDOTHELIN B RECEPTOR
S6	0	S5 AND S4
S7	1040	S1 AND CANCER?
S8	0	S7 AND S5
S9	0	S7 AND ENDOTHELIAL ANTAGONIST?
S10	3690	SY AND TREAT?
S11	132	S7 AND TREAT?

?s s11 and BQ788
 132 S11
 901 BQ788
 S12 0 S11 AND BQ788
 ?s BQ788
 S13 901 BQ788
 ?s s13 and s1
 901 S13
 3306 S1
 S14 0 S13 AND S1
 ?s s13 and s3
 901 S13
 16499 S3
 S15 1 S13 AND S3
 ?t s15/5/all

15/5/1 (Item 1 from file: 349)
 DIALOG(R)File 349:PCT Fulltext
 (c) 2001 WIPO/Univentio. All rts. reserv.

00754503

CANCER TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS
THERAPIE ANTICANCEREUSE FAISANT APPEL A DES ANTAGONISTES DU RECEPTEUR DE
L'ENDOTHELINE

Patent Applicant/Assignee:

NEW YORK UNIVERSITY, 550 First Avenue, New York, NY 10016, US, US
 (Residence), US (Nationality)

Inventor(s):

SCHNEIDER Robert J, Apartment 15M, 70 East 10th Street, New York, NY
 10003, US

JAMAL Sumayah, 24 Gramercy Park, South, New York, NY 10003, US

Legal Representative:

CORUZZI Laura A, Pennie & Edmonds LLP, 1155 Avenue of the Americas, New
 York, NY 10036, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200067024 A1 20001109 (WO 0067024)

Application: WO 2000US11990 20000503 (PCT/WO US0011990)

Priority Application: US 99305084 19990504

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE

DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC

LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK

SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: G01N-033/53

International Patent Class: G01N-033/567; A01N-037/18; A61K-038/00;
C07K-014/00; C07K-016/00; C07K-017/00; C07K-002/00; C07K-004/00;
C07K-005/00; C07K-007/00

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 21420

English Abstract

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

French Abstract

La presente invention concerne des protocoles therapeutiques et des compositions pharmaceutiques destines a traiter et prevenir le cancer. L'invention se rapporte, en particulier, a un nouveau procede permettant de traiter le cancer a l'aide d'antagonistes du recepteur de l'endotheline B (ETB) ou a des formes mimetiques inactives de l'endotheline 1. Les compositions pharmaceutiques de l'invention sont capables d'inhiber selectivement les evenements precoces associes au developpement du cancer. L'invention concerne en outre des analyses de criblage permettant d'identifier des composes qui inhibent l'activation de l'ETB.

Legal Status (Type, Date, Text)

Publication 20001109 A1 With international search report.

Publication 20001109 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

Examination 20010802 Request for preliminary examination prior to end of 19th month from priority date

?ds

Set	Items	Description
S1	3306	E-CADHERIN
S2	0	S1 AND ENDOTHELIN B RECEPTOR
S3	16499	CATENIN?
S4	1160	S3 AND S1
S5	4105	ENDOTHELIN B RECEPTOR
S6	0	S5 AND S4
S7	1040	S1 AND CANCER?
S8	0	S7 AND S5
S9	0	S7 AND ENDOTHELIN ANTAGONIST?
S10	3690	SY AND TREAT?
S11	132	S7 AND TREAT?
S12	0	S11 AND BQ788
S13	901	BQ788
S14	0	S13 AND S1
S15	1	S13 AND S3

?s s7 and endothelin

1040 S7

88708 ENDOTHELIN

S16 0 S7 AND ENDOTHELIN

?s s7 and endothelin receptor?

1040 S7

7609 ENDOTHELIN RECEPTOR?

S17 0 S7 AND ENDOTHELIN RECEPTOR?

?s s7 and treat?

1040 S7

8141373 TREAT?
S18 132 S7 AND TREAT?
?s s18 and melanoma
132 S18
252301 MELANOMA
S19 4 S18 AND MELANOMA

?rd

>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 447.
>>>Duplicate detection is not supported for File 349.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
S20 2 RD (unique items)
?t s20/5/all

20/5/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

13076400 BIOSIS NO.: 200100283549

The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin.

AUTHOR: Kitada Takatoshi; Miyoshi Eiji; Noda Katsuhisa; Higashiyama Shigeki
; Ihara Hideyuki; Matsuura Nariaki; Hayashi Norio; Kawata Sumio;
Matsuzawa Yuji; Taniguchi Naoyuki(a)

AUTHOR ADDRESS: (a)Department of Biochemistry, Osaka University Graduate
School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871:
proftani@biochem.med.osaka-u.ac.jp**Japan

JOURNAL: Journal of Biological Chemistry 276 (1):p475-480 January 5, 2001

MEDIUM: print

ISSN: 0021-9258

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: The enzyme GnT-III (beta1,4-N-acetylglucosaminyltransferase III) catalyzes the addition of a bisecting N-acetylglucosamine (GlcNAc) residue on glycoproteins. Our previous study described that the transfection of GnT-III into mouse *melanoma* cells results in the enhanced expression of E-cadherin, which in turn leads to the suppression of lung metastasis. It has recently been proposed that the phosphorylation of a tyrosine residue of beta-catenin is associated with cell migration. The present study reports on the importance of bisecting GlcNAc residues by GnT-III on tyrosine phosphorylation of beta-catenin using three types of *cancer* cell lines. An addition of bisecting GlcNAc residues to E-cadherin leads to an alteration in cell morphology and the localization of beta-catenin after epidermal growth factor stimulation. These changes are the result of a down-regulation in the tyrosine phosphorylation of beta-catenin. In addition, tyrosine phosphorylation of beta-catenin by transfection of constitutively active c-src was suppressed in GnT-III transfectants as well as in the case of epidermal growth factor stimulation. *Treatment* with tunicamycin abolished any differences in beta-catenin phosphorylation for the mock vis a vis the GnT-III transfectants. Thus, the addition of a specific N-glycan structure, the bisecting GlcNAc to E-cadherin-beta-catenin complex, down-regulates the intracellular signaling pathway, suggesting its implication in cell motility and the suppression of *cancer* metastasis.

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Methods and Techniques

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: B16-hm cell line (Muridae)--mouse *melanoma* cell; Huh7 cell line (Hominidae)--human hepatoma cell; WiDr cell line (Hominidae)--human colon *cancer* cell
 BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Primates; Rodents; Vertebrates
 DISEASES: lung metastasis--neoplastic disease, respiratory system disease; *melanoma*--neoplastic disease
 CHEMICALS & BIOCHEMICALS: *E-cadherin*; beta-catenin--down-regulation, tyrosine phosphorylation; bisecting N-acetylglucosamine residues--addition
 MISCELLANEOUS TERMS: *cancer* metastasis--suppression; cell motility
 ALTERNATE INDEXING: Lung Neoplasms (MeSH); *Melanoma* (MeSH)
 CONCEPT CODES:
 10060 Biochemical Studies-General
 02506 Cytology and Cytochemistry-Animal
 02508 Cytology and Cytochemistry-Human
 10064 Biochemical Studies-Proteins, Peptides and Amino Acids
 16006 Respiratory System-Pathology
 24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
 BIOSYSTEMATIC CODES:
 86215 Hominidae
 86375 Muridae

20/5/2 (Item 2 from file: 5)
 DIALOG(R) File 5:Biosis Previews(R)
 (c) 2001 BIOSIS. All rts. reserv.

13057497 BIOSIS NO.: 200100264646
Tumor heterogeneity and tumor cell-extracellular matrix interactions are essential for the development of patterned tubular intratumoral channels in aggressive prostate *cancer*.
 AUTHOR: Sharma Navesha(a); Seftor Richard E B(a); Lubaroff David M(a); Heidger Paul M(a); Hendrix Mary J C(a)
 AUTHOR ADDRESS: (a)University of Iowa College of Medicine, 51, Newton Road, Iowa City, IA, 52242**USA
 JOURNAL: FASEB Journal 15 (5):pA1078 March 8, 2001
 MEDIUM: print
 CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
 ISSN: 0892-6638
 RECORD TYPE: Abstract
 LANGUAGE: English
 SUMMARY LANGUAGE: English

ABSTRACT: The in situ formation of primitive vascular networks in uveal *melanoma*-- a phenomenon involving the formation of patterned networks by tumor cells in 3-D cultures which "mimic" patterned networks formed during embryonic vasculogenesis, has been termed tumor cell vasculogenesis. Our results utilizing rat prostate tumors and neoplastic prostate cell lines strongly support the concept that "vasculogenic mimicry" is exhibited by aggressive, but not nonaggressive, prostate neoplasms. The tubular networks formed by aggressive rat and human prostate *cancer* cell lines are lined by desmosomally connected cells, conduct dyes reminiscent of microvascular circulation networks, and express various matrix metalloproteinases and vascular markers. Green fluorescent protein labeling of individual clonal rat cell populations reveals the requirement of the E-cadherin positive, R3327-5'B cells along the tubular linings, while the fibroblast-like cell populations (R3327-5'A or R3327-5'C) form the supporting architecture, suggesting compartmentalized roles for individual tumor cell populations. The presence of these channelized networks in vivo coincides with a lack of tumor necrosis and occurs in close proximity to conventional endothelial lined vasculature. Aggressive prostate tumor cells possess the ability to

contract floating collagen gels, indicative of their biomechanical remodeling ability. Individual populations also secrete angiogenic factors and express vascular markers that could facilitate both angiogenesis and vasculogenic mimicry. Channeled tubular network formation in 3-D matrices and contraction of floating collagen gels can be abrogated using CMT-3, an inhibitor of matrix metalloproteinase function. Additionally, these networks express the alpha6beta1 laminin receptor, demonstrate laminin expression, and can be disrupted using a laminin-blocking antibody. These results elucidate key mechanisms involved in tumor cell vasculogenic mimicry, and help illustrate how aggressive tumor cells mimic other cell types as they remodel their environment, providing novel prognostic markers and *treatment* strategies.

REGISTRY NUMBERS: 141907-41-7: MATRIX METALLOPROTEINASES

DESCRIPTORS:

MAJOR CONCEPTS: Cardiovascular System (Transport and Circulation); Tumor Biology

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: rat (Muridae)

ORGANISMS: PARTS ETC: B cell--blood and lymphatics, immune system; vascular networks--circulatory system

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

DISEASES: prostate *cancer*--neoplastic disease, reproductive system disease/male, urologic disease; uveal *melanoma*--eye disease, neoplastic disease

CHEMICALS & BIOCHEMICALS: CMT-1; *E-cadherin*; alpha-6-beta-1--laminin receptor; matrix metalloproteinases

MISCELLANEOUS TERMS: embryonic vasculogenesis; tumor cell vasculogenesis; tumor cell-extracellular matrix interactions; tumor heterogeneity; Meeting Abstract

ALTERNATE INDEXING: Prostatic Neoplasms (MeSH); Uveal Neoplasms (MeSH)

CONCEPT CODES:

02506 Cytology and Cytochemistry-Animal
00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
10802 Enzymes-General and Comparative Studies; Coenzymes
14504 Cardiovascular System-Physiology and Biochemistry
15002 Blood, Blood-Forming Organs and Body Fluids-Blood and Lymph Studies
15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies
15506 Urinary System and External Secretions-Pathology
16506 Reproductive System-Pathology
20006 Sense Organs, Associated Structures and Functions-Pathology
24003 Neoplasms and Neoplastic Agents-Immunology
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
34502 Immunology and Immunochemistry-General; Methods
34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology

BIOSYSTEMATIC CODES:

86375 Muridae

?ds

Set	Items	Description
S1	3306	E-CADHERIN
S2	0	S1 AND ENDOTHELIN B RECEPTOR
S3	16499	CATENIN?
S4	1160	S3 AND S1
S5	4105	ENDOTHELIN B RECEPTOR
S6	0	S5 AND S4
S7	1040	S1 AND CANCER?
S8	0	S7 AND S5
S9	0	S7 AND ENDOTHELIAL ANTAGONIST?
S10	3690	SY AND TREAT?

S11 132 S7 AND TRF ?
 S12 0 S11 AND BQ788
 S13 901 BQ788
 S14 0 S13 AND S1
 S15 1 S13 AND S3
 S16 0 S7 AND ENDOTHELIN
 S17 0 S7 AND ENDOTHELIN RECEPTOR?
 S18 132 S7 AND TREAT?
 S19 4 S18 AND MELANOMA
 S20 2 RD (unique items)

?s s18 and downregulation

132 S18

42087 DOWNREGULATION

S21 6 S18 AND DOWNREGULATION

?rd

>>>Duplicate detection is not supported for File 340.

>>>Duplicate detection is not supported for File 344.

>>>Duplicate detection is not supported for File 348.

>>>Duplicate detection is not supported for File 447.

>>>Duplicate detection is not supported for File 349.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S22 3 RD (unique items)

?t s22/5/all

22/5/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

13117806 BIOSIS NO.: '200100324955

Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells.

AUTHOR: Fujimoto Koji; Sheng Hongmiao; Shao Jinyi; Beauchamp R Daniel(a)

AUTHOR ADDRESS: (a)Department of Surgery, Vanderbilt University Medical Center, 1161 21st Avenue South, CC-2306 Medical Center North, Nashville, TN, 37232-2279; daniel.beauchamp@mcmail.vanderbilt.edu**USA

JOURNAL: Experimental Cell Research 266 (2):p239-249 June 10, 2001

MEDIUM: print

ISSN: 0014-4827

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Invasion is a defining event in carcinoma progression. In general, invasive carcinoma is characterized by an epithelial-fibroblastoid conversion associated with loss of cell-cell adhesion receptors such as E-cadherin and beta-catenin. We report here that TGF-beta1 promotes the invasiveness by modulating the alterations of cellular plasticity including a loss of cell-cell contact in Ras-transformed epithelial cells. In order to examine the role of TGF-beta1 in the Ras-induced responses, intestinal epithelial cells expressing a conditionally activated Ha-RasVal12 (RIE-iRas cells) were used in this study. Induced expression of activated Ha-RasVal12 caused morphologic transformation of the RIE-iRas cells with an increase in vimentin expression and a decrease of E-cadherin levels. There was also redistribution of beta-catenin from the cytoplasm to the nucleus after the induction of Ras. TGF-beta1 *treatment* enhanced both the decrease in E-cadherin levels and the redistribution of beta-catenin. Interestingly, the activation of Ras markedly decreased the level of TGF-beta receptor type II (TbetaRII) in RIE-iRas cells. However, the expression of plasminogen activator inhibitor-1, which is known to be transcriptionally induced by TGF-beta1, was strongly induced by TGF-beta1 despite the marked *downregulation* of TbetaRII. The induction of Ha-RasVal12 markedly increased the invasiveness in RIE-iRas cells, as evaluated by a collagen type I-coated Boyden-chamber assay, and the Ras-mediated

. invasiveness was significantly enhanced by TGF-beta1 *treatment*. Expression of a dominant-negative form of TbetaRII in the RIE-iRas cells abrogated both growth-inhibitory and invasion responses to TGF-beta1. Collectively, these results suggest that TGF-beta1 and oncogenic Ras collaborate in promoting cellular invasiveness in intestinal epithelial cells. The enhancement of invasiveness was correlated with decreased E-cadherin levels and subcellular distribution of beta-catenin. The enhancement of oncogenic Ras-mediated cell transformation by TGF-beta1 occurs via TbetaRII.

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cell Biology; Digestive System (Ingestion and Assimilation); Tumor Biology

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: RIE-iRas (Muridae)--rat intestinal epithelial cells

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

DISEASES: colorectal *cancer*--digestive system disease, neoplastic disease

CHEMICALS & BIOCHEMICALS: *E-cadherin*; activated Ras; beta-catenin; transforming growth factor-beta receptor type II; transforming growth factor-beta-1

MISCELLANEOUS TERMS: cellular transformation; tumor invasiveness

ALTERNATE INDEXING: Colorectal Neoplasms (MeSH)

CONCEPT CODES:

10060 Biochemical Studies-General
02502 Cytology and Cytochemistry-General
02506 Cytology and Cytochemistry-Animal
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
14004 Digestive System-Physiology and Biochemistry
14006 Digestive System-Pathology
17002 Endocrine System-General
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects

BIOSYSTEMATIC CODES:

86375 Muridae

22/5/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

12819155 BIOSIS NO.: 200100026304

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate *cancer* clones expressing distinct cellular and molecular properties not present in parental androgen-dependent *cancer* cells.

AUTHOR: Tso Cho-Lea; McBride William H; Sun Jirong; Patel Belur; Tsui Ke-Hung; Paik Sun H; Gitlitz Barbara; Caliliw Randy; van Ophoven Arndt; Wu Lily; deKernion Jean; Belldegrun Arie(a)

AUTHOR ADDRESS: (a)Department of Urology, UCLA School of Medicine, CHS 66-118, Los Angeles, CA, 90095-1738**USA

JOURNAL: Cancer Journal 6 (4):p220-233 July-August, 2000

MEDIUM: print

ISSN: 1528-9117

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: PURPOSE The mechanism of progression of human prostate *cancer* (CaP) cells under androgen ablation therapy remains unclear. To study the alternative pathways of CaP cell growth under conditions of androgen deprivation, androgen-independent CaP variants were selected and expanded from an androgen-dependent CaP line via an in vitro androgen deprivation *treatment*. Cellular and molecular properties of these

androgen-independent variants were characterized both in vitro and in vivo and compared with those of their parental androgen-dependent cells. METHODS Androgen deprivation *treatment* of an androgen-dependent CaP cell line, LNCaP, was carried out by replacing culture medium with RPMI 1640 medium plus 10% charcoal-stripped serum. Cells that survived through the androgen deprivation *treatment* were harvested and expanded in the androgen-deficient culture medium and were designated CL-1. The CL-1 cells were also recultured in androgen-containing medium and designated CL-2. The growth (cell cycle analysis, 3H-thymidine incorporation assay, growth expansion, and colonization efficiency), expression of CaP-associated markers (semiquantitative reverse transcriptase polymerase chain reaction), interaction with endothelial and bone marrow stromal cells, sensitivity to anticancer agents and radiation (growth inhibition), and tumorigenicity of CL-1 and CL-2 cells were determined and compared with these characteristics in parental LNCaP cells. RESULTS CL-1 and CL-2 cells are fast-growing cells when compared with parental LNCaP cells. They were capable of potentiating the growth of endothelial and bone marrow stromal cells in co-culture experiments and acquired significant resistance to radiation and to anticancer cytotoxic agents (Taxol(R) paclitaxel, vinblastine, and etoposide). In contrast to the poorly tumorigenic parental LNCaP cells, CL-1 and CL-2 lines proved highly tumorigenic, exhibiting invasive and metastatic characteristics in intact and castrated mice or in female mice within a short period of 3 to 4 weeks. No growth supplements (e.g., Matrigel) were needed. When transfected with the green fluorescence protein (GFP) gene and transplanted orthotopically in the accessory sex gland, extensive metastatic disease from the primary CL tumor could be identified in bone, lymph nodes, lung, liver, spleen, kidney, and brain. Semiquantitative reverse transcriptase polymerase chain reaction analysis revealed a markedly distinct molecular expression profile in the CL lines: overexpression of basic fibroblast growth factor, interleukin-6, interleukin-8, vascular endothelial growth factor, transforming growth factor-beta, epidermal growth factor receptor, caveolin, and bcl-2 messenger RNAs and marked down-regulation of E-cadherin, p-53, and pentaerythritol tetranitrate. CONCLUSIONS Early administration of hormonal therapy after failure of first line *treatment* is associated with a profound clonal selection of aggressive AI variants, such as CL-1 and CL-2 lines. These tumor lines, with their parental counterparts, can serve as valuable tools for studying the cellular and molecular mechanisms of CaP progression and metastasis under hormonal therapy. CL-1 and CL-2 offer a unique and reproducible model for the evaluation of drug sensitivity and for other therapeutic modalities for advanced prostate *cancer*.

REGISTRY NUMBERS: 106096-93-9: BASIC FIBROBLAST GROWTH FACTOR; 33419-42-0: ETOPOSIDE; 33069-62-4: PACLITAXEL; 33069-62-4: TAXOL; 78-11-5: PENTAERYTHRITOL TETRANITRATE; 127464-60-2: VASCULAR ENDOTHELIAL GROWTH FACTOR; 865-21-4: VINBLASTINE

DESCRIPTORS:

MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular Biophysics); Cell Biology; Urinary System (Chemical Coordination and Homeostasis); Tumor Biology

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: CL-1 cell line (Hominidae)--androgen-dependent, cellular properties, growth, human prostate *cancer* cells, molecular properties; CL-2 cell line (Hominidae)--androgen-dependent, cellular properties, growth, human prostate *cancer* cells, molecular properties; LNCaP cell line (Hominidae)--androgen-dependent, cellular properties, growth, human prostate *cancer* cells, molecular properties; mouse (Muridae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Primates; Rodents; Vertebrates

DISEASES: prostate *cancer*--hormone refractory, metastatic, neoplastic disease, reproductive system disease/male, urologic disease

CHEMICALS & BIOCHEMICALS: *E-cadherin*--*downregulation*; basic fibroblast growth factor--messenger RNA, overexpression; bcl-2--

* messenger RNA, overexpression; caveolin--messenger RNA overexpression; epidermal growth factor receptor--messenger RNA, overexpression; etoposide--antineoplastic-drug; interleukin-6--messenger RNA, overexpression; interleukin-8--messenger RNA, overexpression; p53--*downregulation*; paclitaxel {Taxol}--antineoplastic-drug; pentaerythritol tetranitrate--*downregulation*; transforming growth factor-beta--messenger RNA, overexpression; vascular endothelial growth factor--messenger RNA, overexpression; vinblastine--antineoplastic-drug

METHODS & EQUIPMENT: semiquantitative reverse transcriptase-polymerase chain reaction--genetic method

MISCELLANEOUS TERMS: androgen deprivation

ALTERNATE INDEXING: Prostatic Neoplasms (MeSH)

CONCEPT CODES:

10064 Biochemical Studies-Proteins, Peptides and Amino Acids
02502 Cytology and Cytochemistry-General
02506 Cytology and Cytochemistry-Animal
02508 Cytology and Cytochemistry-Human
03502 Genetics and Cytogenetics-General
03506 Genetics and Cytogenetics-Animal
03508 Genetics and Cytogenetics-Human
10060 Biochemical Studies-General
10062 Biochemical Studies-Nucleic Acids, Purines and Pyrimidines
12512 Pathology, General and Miscellaneous-Therapy (1971-)
15504 Urinary System and External Secretions-Physiology and Biochemistry
15506 Urinary System and External Secretions-Pathology
16506 Reproductive System-Pathology
17002 Endocrine System-General
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy

BIOSYSTEMATIC CODES:

86215 Hominidae
86375 Muridae

22/5/3 (Item 3 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11981435 BIOSIS NO.: 199900234748

E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.

AUTHOR: De Marzo Angelo M(a); Knudsen Beatrice; Chan-Tack Kirk; Epstein Jonathan I

AUTHOR ADDRESS: (a)Department of Pathology, 720 Rutland Avenue, Ross 512B, Baltimore, MD, 21205**USA

JOURNAL: Urology 53 (4):p707-713 April, 1999

ISSN: 0090-4295

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Objectives. Approximately 30% of clinically localized prostate adenocarcinomas *treated* by radical prostatectomy (RP) will recur within 10 years. To prevent recurrence, new adjuvant therapies are in development that seek to *treat* high-risk patients after surgery. To identify patients as candidates for these *treatments*, improved biomarkers for predicting prognosis are needed. Reduced expression of E-cadherin has been proposed as a new marker for predicting prognosis in prostate adenocarcinoma. Since few studies have examined the relation between risk factors for disease progression and E-cadherin expression using routinely processed RP specimens, we used RP specimens to correlate *downregulation* of E-cadherin and pathologic stage at RP. Methods. Primary adenocarcinomas (n = 76) from formalin-fixed and

paraffin-embedded RP specimens were evaluated by immunohistochemistry against E-cadherin (HECD-2) using heat-induced epitope retrieval and automated staining (BioTek Solutions). Normal appearing prostate epithelium was used as an internal control for each specimen. Staining was scored as an estimate of the percentage of tumor cells in each specimen that showed strong plasma membrane staining. Results. Specimens were divided into three categories with respect to Gleason score: intermediate (score 5 to 6, n = 31), intermediate to high (score 7, n = 25), and high (score 8 to 9, n = 20). For pathologic stage, specimens were divided into three categories: low stage/organ confined (pT2, n = 30), intermediate stage/limited extraprostatic extension (pT3a, n = 25), and high stage/seminal vesicle-pelvic lymph node metastases (pT3b-any pTN 1, n = 21). In univariate analysis, reduced levels of E-cadherin correlated with advanced Gleason score (P = 0.003) and advanced pathologic stage (P = 0.008). In multivariate analysis, E-cadherin, preoperative prostate-specific antigen, and Gleason score all contributed independently to the prediction of high-stage disease (P < 0.0001). Ten pelvic lymph node metastases from this same patient cohort were stained for E-cadherin. All were positive and 9 of 10 were moderately to strongly positive. Conclusions. Since essentially all patients in the high-stage category have a very high likelihood of disease recurrence, we conclude that the study of E-cadherin in a prospective manner as a potential biomarker of disease progression in patients with clinically organ-confined prostate *cancer* who undergo RP is warranted. Additionally, our finding that most metastatic tumor cells in pelvic lymph nodes express E-cadherin supports the notion that the establishment of the distant colonization and growth of metastatic tumor cells may be facilitated by expression or re-expression of previously downregulated E-cadherin. This would strongly suggest that irreversible genetic inactivation through mutation or allelic loss at 16q2.3 is probably not the mechanism of E-cadherin *downregulation* in most abnormally expressing primary prostate carcinomas.

DESCRIPTORS:

MAJOR CONCEPTS: Tumor Biology

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: human (Hominidae)--male, patient

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Primates; Vertebrates

DISEASES: prostate *cancer*--neoplastic disease, tumor aggressiveness, surgical *treatment*, urologic disease, reproductive system disease/male

CHEMICALS & BIOCHEMICALS: *E-cadherin*--tumor aggressiveness marker, tumor specimen expression

METHODS & EQUIPMENT: radical prostatectomy--surgical method

ALTERNATE INDEXING: Prostatic Neoplasms (MeSH)

CONCEPT CODES:

24006 Neoplasms and Neoplastic Agents-Biochemistry
 11105 Anatomy and Histology, General and Comparative-Surgery
 13004 Metabolism-Carbohydrates
 13012 Metabolism-Proteins, Peptides and Amino Acids
 24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy
 16506 Reproductive System-Pathology
 15506 Urinary System and External Secretions-Pathology
 01056 Microscopy Techniques-Histology and Histochemistry
 24007 Neoplasms and Neoplastic Agents-Carcinogens and Carcinogenesis
 10064 Biochemical Studies-Proteins, Peptides and Amino Acids
 16501 Reproductive System-General; Methods
 15501 Urinary System and External Secretions-General; Methods
 12512 Pathology, General and Miscellaneous-Therapy (1971-)
 11108 Anatomy and Histology, General and Comparative-Microscopic and Ultramicroscopic Anatomy
 10068 Biochemical Studies-Carbohydrates

BIOSYSTEMATIC CODES:

86215 Hominidae

?ds

Set	Items	Description
S1	3306	E-CADHERIN
S2	0	S1 AND ENDOTHELIN B RECEPTOR
S3	16499	CATENIN?
S4	1160	S3 AND S1
S5	4105	ENDOTHELIN B RECEPTOR
S6	0	S5 AND S4
S7	1040	S1 AND CANCER?
S8	0	S7 AND S5
S9	0	S7 AND ENDOTHELIN ANTAGONIST?
S10	3690	SY AND TREAT?
S11	132	S7 AND TREAT?
S12	0	S11 AND BQ788
S13	901	BQ788
S14	0	S13 AND S1
S15	1	S13 AND S3
S16	0	S7 AND ENDOTHELIN
S17	0	S7 AND ENDOTHELIN RECEPTOR?
S18	132	S7 AND TREAT?
S19	4	S18 AND MELANOMA
S20	2	RD (unique items)
S21	6	S18 AND DOWNREGULATION
S22	3	RD (unique items)
?s 18 and administer compound		
	3152795	18
	0	ADMINISTER COMPOUND
S23	0	18 AND ADMINISTER COMPOUND
?s s18 and administer?		
	132	S18
	1060615	ADMINISTER?
S24	0	S18 AND ADMINISTER?
?		